ViiV Healthcare Reclaims Top Spot in Pharma Reputation Ranking Among U.S. Patient Groups

ViiV Healthcare has once again demonstrated its commitment to patient-centric practices, reclaiming the number one position in the latest U.S.-specific reputation survey conducted by PatientView. This accolade follows the company’s successful ranking in the global version of the survey, marking a continued ascent in patient group esteem after slipping from its previous standings in recent years. The survey’s results provide valuable insights into the pharmaceutical industry’s perception among U.S. patient advocates, representing the voices of over 13 million patients across various therapeutic areas including cancer, rare diseases, and neurological conditions.

Survey Overview and Methodology

The latest report released by PatientView summarizes findings from a survey conducted over several months—from December 2024 to March 2025. In total, 372 patient groups were surveyed, rating the reputation of 40 global pharmaceutical companies in regard to their performance and integrity in the healthcare realm. In a compelling repeat of past accolades, ViiV Healthcare emerged as the frontrunner, overtaking Servier and Amgen, last year’s leaders in patient group satisfaction.

Key Findings from the PatientView Survey

In this year’s evaluation, respondents not only ranked the general corporate reputations of these major pharmaceutical companies but also provided ratings based on their direct experiences with these firms. Impressively, ViiV Healthcare was highly rated even by its peers. Specifically, when the criteria were narrowed solely to firms with which the patient groups had direct interactions, ViiV once again led the way, followed closely by Servier and Amgen.

Pharma Industry Reputation on the Rise

The survey also gathered input on the overall perceptions of the pharmaceutical industry in the U.S. A notable 60% of patient groups rated the industry’s reputation as either “good” or “excellent,” indicating a positive shift from the previous year’s figures—up from 57%—and surpassing this year’s global survey findings of 56% in support for the industry as a whole. Despite this positive trend, the pharmacological industry still falls behind its biotech counterparts, where a striking 74% of patient advocates reflected a positive view.

Areas of Improvement and Decline

To delve deeper into the aspects of performance, the survey showed that ratings for various qualities perceived by patient groups saw a considerable decline since 2020. The most notable decreases were seen in integrity, patient safety, and patient-centricity, which fell by 15, 14, and 10 percentage points respectively over four years. Despite the downward trend in most performance categories, a slight improvement was recorded in pricing transparency, which rose by a single percentage point. Transparency in funding has notably remained stable at a positive rating of 32% since 2020.

Best-Rated Qualities of the Pharma Industry

The survey did highlight some strengths in the pharmaceutical industry’s performance, particularly in areas that directly benefit patients. A commendable 77% of patient groups rated the industry’s product offerings as “good” or “excellent”—a testament to the pharmaceutical sector’s ongoing commitment to innovation. Other aspects that received positive feedback included:

• Ensuring patient safety: 64% rated positively.
• Innovation: 63% received favorable ratings.
• Patient group relations: 60% described interactions positively.
• Information dissemination: 57% rated well.
• Patient-centricity: 50% received positive feedback.

However, integrity, albeit high in importance, saw its ratings dip slightly below the half mark, with only 49% of patient groups viewing this quality favorably.

Conclusion

In summary, ViiV Healthcare’s return to the forefront of pharma reputation rankings shines a light on the importance of accountability and transparency within the industry. While the overall perception of the pharmaceutical industry has improved, critical areas still require attention and improvement, particularly concerning integrity and other patient-centric practices. Future opportunities exist for all pharmaceutical companies to enhance their standing among patient groups by addressing these challenges head-on. ViiV’s ongoing dedication to prioritizing patient needs serves as an exemplary model for others in the industry.